580 related articles for article (PubMed ID: 33292688)
21. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
22. Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Toews K; Grunewald L; Schwiebert S; Klaus A; Winkler A; Ali S; Zirngibl F; Astrahantseff K; Wagner DL; Henssen AG; Deubzer HE; Schulte JH; Ochsenreither S; Eggert A; Künkele A
Mol Carcinog; 2020 Jul; 59(7):724-735. PubMed ID: 32333465
[TBL] [Abstract][Full Text] [Related]
23. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
24. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis.
Qin L; Cui Y; Yuan T; Chen D; Zhao R; Li S; Jiang Z; Wu Q; Long Y; Wang S; Tang Z; Pan H; Li X; Wei W; Yang J; Luo X; Zhang Z; Tang Q; Liu P; Weinkove R; Yao Y; Qin D; Thiery JP; Li P
Nat Commun; 2022 Oct; 13(1):6051. PubMed ID: 36229619
[TBL] [Abstract][Full Text] [Related]
25. Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models.
Imai K; Takeuchi Y; Terakura S; Okuno S; Adachi Y; Osaki M; Umemura K; Hanajiri R; Shimada K; Murata M; Kiyoi H
Mol Cancer Ther; 2024 Mar; 23(3):381-393. PubMed ID: 37828726
[TBL] [Abstract][Full Text] [Related]
26. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.
Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603
[TBL] [Abstract][Full Text] [Related]
27. Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer.
Yang CY; Fan MH; Miao CH; Liao YJ; Yuan RH; Liu CL
Mol Ther Oncolytics; 2020 Jun; 17():571-585. PubMed ID: 32637575
[TBL] [Abstract][Full Text] [Related]
28. Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma.
Jiang W; Li T; Guo J; Wang J; Jia L; Shi X; Yang T; Jiao R; Wei X; Feng Z; Tang Q; Ji G
Front Oncol; 2021; 11():546586. PubMed ID: 33777728
[TBL] [Abstract][Full Text] [Related]
29. Targeting PD-L1 in non-small cell lung cancer using CAR T cells.
Liu M; Wang X; Li W; Yu X; Flores-Villanueva P; Xu-Monette ZY; Li L; Zhang M; Young KH; Ma X; Li Y
Oncogenesis; 2020 Aug; 9(8):72. PubMed ID: 32792499
[TBL] [Abstract][Full Text] [Related]
30. The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2
Li P; Yang L; Li T; Bin S; Sun B; Huang Y; Yang K; Shan D; Gu H; Li H
Front Oncol; 2020; 10():1143. PubMed ID: 32766150
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
[TBL] [Abstract][Full Text] [Related]
32. Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy.
He H; Liao Q; Zhao C; Zhu C; Feng M; Liu Z; Jiang L; Zhang L; Ding X; Yuan M; Zhang X; Xu J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615704
[TBL] [Abstract][Full Text] [Related]
33. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
34. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.
Shabaneh TB; Stevens AR; Stull SM; Shimp KR; Seaton BW; Gad EA; Jaeger-Ruckstuhl CA; Simon S; Koehne AL; Price JP; Olson JM; Hoffstrom BG; Jellyman D; Riddell SR
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38325903
[TBL] [Abstract][Full Text] [Related]
35. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
36. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
37. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.
Myers Chen K; Grun D; Gautier B; Venkatesha S; Maddox M; Zhang AH; Andersen P
Front Immunol; 2024; 15():1380065. PubMed ID: 38726005
[TBL] [Abstract][Full Text] [Related]
38. [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor].
Zhong H; Zou Q; Liu H; Wang X; DU S; Liang H; Wu Z; Ye J; Zou Q
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1877-1884. PubMed ID: 35012922
[TBL] [Abstract][Full Text] [Related]
39. A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis.
Ma Q; He X; Zhang B; Guo F; Ou X; Yang Q; Shu P; Chen Y; Li K; Gao G; Zhu Y; Qin D; Tang J; Li X; Jing M; Zhao J; Mo Z; Liu N; Zeng Y; Zhou K; Feng M; Liao W; Lei W; Li Q; Li D; Wang Y
Signal Transduct Target Ther; 2022 Nov; 7(1):380. PubMed ID: 36402752
[TBL] [Abstract][Full Text] [Related]
40. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
Huang SW; Pan CM; Lin YC; Chen MC; Chen Y; Jan CI; Wu CC; Lin FY; Wang ST; Lin CY; Lin PY; Huang WH; Chiang YT; Tsai WC; Chiu YH; Lin TH; Chiu SC; Cho DY
Adv Sci (Weinh); 2023 Jun; 10(17):e2206856. PubMed ID: 37078788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
